2416 / 2894
195. Golding LAR: Postcardiotomy mechanical support.
Semin Thorac Cardiovasc Surg 3:29, 1991.
196. Walters HL, 3rd, Hakimi M, Rice MD, et al: Pediatric
cardiac surgical ECMO: Multivariate analysis of
risk factors for hospital death. Ann Thorac Surg
60:329, 1995, discussion 336.
197. Meliones JN, Custer JR, Snedecor S, et al: Extracor-
poreal life support for cardiac assist in pediatric
patients: Review of ELSO Registry data. Circulation
84(5 Suppl)III-168, 1991.
198. Duncan BW, Ibrahim AE, Hraska V, et al: Use of
rapid-deployment extracorporeal membrane oxy-
genation for the resuscitation of pediatric patients
with heart disease after cardiac arrest. J Thorac Car-
diovasc Surg 116:305, 1998.
199. Karl TR: Extracorporeal circulatory support in
infants and children. SeminThorac Cardiovasc Surg
6:54, 1994.
200. Atz AM, Wessel DL: Sildenafil ameliorates effects of
inhaled nitric oxide withdrawal. Anesthesiology
91:307-310, 1999.
201. Runo JR, Loyd JE: Primary pulmonary hyperten-
sion. Lancet 361:1533-1544, 2003.
202. Clabby ML, Canter CE, Mollen JH, et al: Hemody-
namic data and survival in children with pulmonary
hypertension. J Am Coll Cardiol 30:554-560, 1997.
203. Rich S, Dantzker DR, Ayres SM, et al: Primary pul-
monary hypertension: A national prospective study.
Ann Intern Med 107:216-223, 1987.
204. Cormosino MJ, Friesen RH, Doran A, Ivy DD:
Perioperative complications in children with pul-
monary hypertension undergoing noncardiac
surgery or cardiac catheterization. Anesth Analg
104:521-527, 2007.
205. Taylor CJ, Derrick G, McEwan A, et al: Risk of
cardiac catheterization under anaesthesia in chil-
dren with pulmonary hypertension. Br J Anaesth
98:657-661, 2007.
206. Blaise G, Langleben D, Hubert B: Pulmonary arte-
rial hypertension—pathophysiology and anesthetic
approach. Anesthesiology 99:1415-1432, 2003.
207. Fischer LG, Van Aken H, Burkle H: Management of
pulmonary hypertension: Physiological and phar-
macological considerations for anesthesiolgoists.
Anesth Analg 96:1603-1616, 2003.
208. Adatia I: Recent advances in pulmonary vascular
disease. Curr Opin Pediatr 14:292-297, 2002.
209. Lyrene RK, Welch KA, Godoy G, Philips JB: Alkalo-
sis attenuates hypoxic pulmonary vasoconstriction
in neonatal lambs. Pediatr Res 19:1268, 1985.
210. Rudolph AM, Yuan S: Response of the pulmonary
vasculature to hypoxia and H+ ion concentration
changes. J Clin Invest 45:399, 1966.
211. Weisfeldt ML, Halperin HR: Cardiopulmonary
resuscitation: Beyond cardiac massage. Circulation
74:443, 1986.
212. Wessel DL, Triedman JK, Wernovsky G: Pulmonary
and systemic hemodynamics of amrinone in neo-
nates following cardiopulmonary bypass. Circula-
tion 80(Suppl II):488, 1989.
213. Lawless S, Burckart G, Diven W: Amrinone phar-
macokinetics in neonates and infants. J Clin Phar-
macol 28:283, 1988.
214. Molloy DW: Effects of noradrenaline and isoprote-
renol on cardiopulmonary function in a canine
model of acute pulmonary hypertension. Chest
88:432, 1985.
215. Heymann MA, Hoffman JIE: Persistent pulmonary
hypertension syndromes in the newborn.
In
Weir
EK, Reeves JT (eds): Pulmonary Hypertension. Mt.
Kisko, NY, Futura, 1984, p 45.
216. Bush A, Busset C, Knight WB, et al: Modification
of pulmonary hypertension secondary to congenital
heart disease. Am Rev Respir Dis 136:767, 1987.
217. Zall S, Milocco I, Rickstein S-E: Effects of adenosine
on myocardial blood flow and metabolism after
coronary artery bypass surgery. Anesth Analg
73:689, 1991.
218. Barst RJ, Rubin LJ, McGoon MD, et al: Survival in
primary pulmonary hypertension with long-term
continuous intravenous prostacyclin. Ann Intern
Med 121:409-415, 1994.
219. Barst RJ, Rubin LJ, Long WA, et al: A comparison of
continuous intravenous epoprostenol (prostacy-
clin) with conventional therapy for primary pulmo-
nary hypertension. N Engl J Med 334:296-302,
1996.
220. Prasad S, Wilkinson J, Gatzoulis MA: Sildenafil in
primary pulmonary hypertension. N Engl J Med
343:1342-1343, 2000.
221. Abrams D, Schulze-Nieck I, Magee AG: Sildenafil as
a selective pulmonary vasodilator in childhood
primary pulmonary hypertension. Heart 84:e4-e5,
2000.
222. Zhao L, Mason NA, Morrell NW: Sildenafil inhibits
hypoxia-induced pulmonary hypertension. Circu-
lation 104:424-428, 2001.
223. Barst RJ, Ivy D, Dingemanse J, et al: Pharmacokine-
tics, safety, and efficacy of bosentan in pediatric
patients with pulmonary arterial hypertension. Clin
Pharmacol Ther 73:372-373, 2003.
224. Boucek MM, Edward LB, Berkeley MK, et al: The
registry of the International Society for Heart and
Lung Transplantation: Sixth official pediatric
report—2003. J Heart Lung Transplant 22:636-652,
2003.
225. Gaynor JW, Bridges ND, Clark BJ, et al: Update on
lung transplantation in children. Curr Opin Pediatr
10:256-261, 1998.
226. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, et
al: Inhaled nitric oxide as a cause of selective pul-
monary vasodilatation in pulmonary hypertension.
Lancet 338:1173, 1991.
227. Girard C, Lehot JJ, Clerc J, French P: Inhaled nitric
oxide (NO) in pulmonary hypertension following
mitral valve replacement. Anesthesiology 75:A984,
1991.
228. Russell IA, Zwass MS, Fineman JR, et al: The effects
of inhaled nitric oxide on postoperative pulmonary
hypertension in infants and children undergoing
surgical repair of congenital heart disease. Anesth
Analg 87:46, 1998.
229. Curran RD, Mavroudis C, Backer CL, et al: Inhaled
nitric oxide for children with congenital heart
disease and pulmonary hypertension. Ann Thorac
Surg 60:1765, 1995.
230. Wessel DL, Adatia I, Giglia TM, et al: Use of inhaled
nitric oxide and acetylcholine in the evaluation of
pulmonary hypertension and endothelial function
after cardiopulmonary bypass. Circulation 88(5 Pt
1)2128, 1993.
231. Zobel G, Gamillscheg A, Schwinger W, et al: Inhaled
nitric oxide in infants and children after open-heart
surgery. J Cardiovasc Surg 39:79, 1998.
232. Adatia I, Perry S, Landzberg M, et al: Inhaled nitric
oxide and hemodynamic evaluation of patients with
pulmonary hypertension before transplantation.
J Am Coll Cardiol 25:1656, 1995.
233. Adatia I, Atz AM, Jonas RA, Wessel DL: Diagnostic
use of inhaled nitric oxide after neonatal cardiac
operations. J Thorac Cardiovasc Surg 112:1403,
1996.
234. Bartkowski R, Wojtalik M, Korman E, et al: Thyroid
hormone levels in infants during and after cardio-
pulmonary bypass with ultrafiltration. Eur J Cardio-
thorac Surg 22:879-884, 2002.
235. Hickey PR, Hansen DD: Pulmonary hypertension
in infants: Postoperative management.
In
Yacoub M
(ed): Annual of Cardiac Surgery. London, Current
Science, 1989, pp 16-22.
236. Wheller J, George BL, Mulder DG, et al: Diagnosis
and management of postoperative pulmonary
hypertensive crisis. Circulation 70:1640-1644,
1979.
237. Journois D, Pouard P, Mauriat P, et al: Inhaled nitric
oxide as a therapy for pulmonary hypertension after
operations for congenital heart defects. J Thorac
Cardiovasc Surg 107:1129-1135, 1994.
238. Yahagi N, Kumon K, Tanigami H, et al: Inhaled
nitric oxide for the postoperative management of
Fontan-type operations. Ann Thorac Surg 57:1371-
1372, 1994.
239. Manno CS, Hedberg KW, Kim HC, et al: Compari-
son of the hemostatic effects of fresh whole blood,
stored whole blood, and components after open
heart surgery in children. Blood 77:930, 1991.
240. DietrichW, Mossinger H, Spannagl M, et al: Hemos-
tatic activation during cardiopulmonary bypass
with different aprotinin dosages in pediatric patients
having cardiac operations. J Thorac Cardiovasc Surg
105:712, 1993.
241. Andrew M, Paes B, Milner R, et al: Development of
the human coagulation system in the full-term
infant. Blood 70:165, 1987.
242. Colon-Otero G, Gilchrist GS, Holcomb GR, et al:
Preoperative evaluation of hemostasis in patients
with heart disease. Mayo Clin Proc 62:379, 1987.
243. Vieira A, Berry L, Ofoso F, Andrew M: Heparin sen-
sitivity and resistance in the neonate: An explana-
tion. Thromb Res 63:85, 1991.
244. Kern FH, Morana NJ, Sears J, Hickey PR: Coagula-
tion defects in neonates during CPB. Ann Thorac
Surg 54:541, 1992.
245. Horkay F, Martin P, Rajah SM, Walker DR: Response
to heparinization in adults and children undergoing
cardiac operations. Ann Thorac Surg 53:822, 1992.
246. Jobes DR, Shaffer GW, Aitken GL: Increased accu-
racy and precision of heparin and protamine dosing
reduces blood loss and transfusion in patients
undergoing primary cardiac operations. J Thorac
Cardiovasc Surg 110:36, 1995.
247. Harker LA: Bleeding after cardiopulmonary bypass.
N Engl J Med 314:446, 1986.
248. Woodman RC, Harker LA: Bleeding complications
associated with cardiopulmonary bypass. Blood
76:1680, 1990.
249. Salzman EW, Weinstein MJ, Weintraub RM, et al:
Treatment with desmopressin acetate to reduce
blood loss after cardiac surgery. N Engl J Med
314:1402, 1986.
250. Reynolds LM, Nicolson SC, Jobes DR, et al: Desmo-
pressin does not decrease bleeding after cardiac
operation in young children. J Thorac Cardiovasc
Surg 106:954, 1993.
251. Horrow JC, Hlavacek J, Strong MD, et al: Prophylac-
tic tranexamic acid decreases bleeding after cardiac
operations. J Thorac Cardiovasc Surg 99:70, 1990.
252. Royston D, Taylor KM, Bidstrup BP, Sapsford RN:
Effect of aprotinin on need for blood transfusion
after repeat open-heart surgery. Lancet 2:1289,
1987.
253. Dietrich W, Henze R, Barankay A, et al: High-dose
aprotinin application reduces homologous blood
requirement in cardiac surgery. J Cardiothorac
Anesth 3:79, 1989.
254. Dietrich W, Spannagl M, JochumM, et al: Influence
of high-dose aprotinin treatment on blood loss and
coagulation patterns in patients undergoing myo-
cardial revascularization. Anesthesiology 73:1119,
1990.
255. Dietrich W, Spannagl M, Schramm W, et al: The
influence of preoperative anticoagulation on
2416
Anestesia pediátrica